As compared to CML, in AML cells BIM expression is regulated by post-translational modifications, including its phosphorylation by ERK1/2, resulting in its degradation by the proteasome [16]. The gene discussed is BCL2L11; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.